Rafael(US:RFL)2025-12-11 21:19Financial Performance - Rafael Holdings reported a net loss of $9.8 million, or $0.19 per share, for the first quarter of fiscal 2026, compared to a net loss of $9.0 million, or $0.37 per share, in the same period last year[5]. - Total revenues for the quarter were $240,000, up from $128,000 in the same quarter of the previous year[15]. - Operating loss for the quarter was $10.1 million, compared to an operating loss of $3.8 million in the prior year[15]. - General and administrative expenses rose to $2.8 million for the quarter, compared to $2.5 million in the same period last year[7]. Research and Development - Research and development expenses increased to $7.5 million for the three months ended October 31, 2025, from $1.3 million in the prior year, primarily due to the consolidation of Cyclo Therapeutics' expenses following its acquisition[6]. - The company is progressing in its pivotal Phase 3 TransportNPC™ study for Trappsol Cyclo™, which is aimed at treating Niemann-Pick Disease Type C1[3]. Cash and Assets - Cash and cash equivalents as of October 31, 2025, were $45.5 million, down from $52.8 million as of July 31, 2025[4]. - Total current assets decreased to $48.3 million as of October 31, 2025, from $56.7 million as of July 31, 2025[12]. - The accumulated deficit increased to $242.1 million as of October 31, 2025, from $232.3 million as of July 31, 2025[12]. - Total equity attributable to Rafael Holdings decreased to $85.2 million as of October 31, 2025, from $94.4 million as of July 31, 2025[12].